AstraZeneca Pays $102 Million For Sumitomo Shares Of Japan Unit
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca said it has paid $102 million for all the shares Sumitomo Chemical held in AstraZeneca K.K. of Japan, giving the UK-based company full control of its unit.
AstraZeneca said it has paid $102 million for all the shares Sumitomo Chemical held in AstraZeneca K.K. of Japan, giving the UK-based company full control of its unit. AZ said it did so because it sees Japan as a key growth platform, particularly since it has made efforts to speed up its process for drug approvals. AZ has been undergoing a restructuring in the wake of patent protection losses of key drugs, looking to Asia to fill the sales void. (Click here for more)
"AstraZeneca Takes Control Of Japanese Unit" - Genetic Engineering & Biotechnology News (U.S.) (3/27/2014)